Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211

Molecular Pharmacology

Volumn 85, Issue 1, 2014, Pages 116-126

  Scholten, Danny J ^a   Roumen, Luc ^a   Wijtmans, Maikel ^a   Verkade Vreeker, Marlies C A ^a   Custers, Hans ^a   Lai, Michael ^a   De Hooge, Daniela ^a   Canals, Meritxell ^a,b   De Esch, Iwan J P ^a   Smit, Martine J ^a   De Graaf, Chris ^a   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 6 CHLORO 5 [4 (1 (4 CHLOROBENZYL)PIPERIDIN 4 YL) 3 ETHYLPIPERAZIN 1 YL]PYRAZINE 2 CARBOXAMIDE; 5 CHLORO 6 [4 (1 (4 CHLOROBENZYL)PIPERIDIN 4 YL) 3 ETHYLPIPERAZIN 1 YL] N ETHYLNICOTINAMIDE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; CXCL11 CHEMOKINE I 125; MARAVIROC; NBI 74330; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VUF 11211;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL MEMBRANE; COMPUTER MODEL; DRUG BINDING SITE; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR INTERACTION; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTON TRANSPORT; SITE DIRECTED MUTAGENESIS;

EID: 84890653833     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.088633     Document Type: Article

References (52)

1. Balevicius V, Bariseviciute R, Aidas K, Svoboda I, Ehrenberg H, and Fuess H (2007) Proton transfer in hydrogen-bonded pyridine/acid systems: The role of higher aggregation. Phys Chem Chem Phys 9:3181-3189.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in Receptor Molecular Biology, Vol. 25 (Sealfon SC, ed) pp 366-428, Academic Press, Waltham, MA.
3. Bernat V, Heinrich MR, Baumeister P, Buschauer A, and Tschammer N (2012) Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3. ChemMedChem 7:1481-1489.
4. Casarosa P, Menge WM, Minisini R, Otto C, van Heteren J, Jongejan A, Timmerman H, Moepps B, Kirchhoff F, and Mertens T et al. (2003) Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G proteincoupled receptor. J Biol Chem 278:5172-5178.
5. de Graaf C, Foata N, Engkvist O, and Rognan D (2008) Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening. Proteins 71:599-620.
6. de Kruijf P, Lim HD, Roumen L, Renjaän VA, Zhao J, Webb ML, Auld DS, Wijkmans JCHM, Zaman GJR, and Smit MJ et al. (2011) Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 80:1108-1118.
7. de Mendonça FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, and Pease JE (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280:4808-4816.
8. Elling CE, Frimurer TM, Gerlach LO, Jorgensen R, Holst B, and Schwartz TW (2006) Metal ion site engineering indicates a global toggle switch model for seventransmembrane receptor activation. J Biol Chem 281:17337-17346.
9. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, Wodak SJ, Vassart G, Pardo L, and Parmentier M (2001) The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem 276:13217-13225.
10. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, and Schwarz D et al. (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 313:1263-1271.
11. Jenh CH, Cox MA, Cui L, Reich EP, Sullivan L, Chen SC, Kinsley D, Qian S, Kim SH, and Rosenblum S et al. (2012) A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol 13:2.
12. Jensen PC, Nygaard R, Thiele S, Elder A, Zhu G, Kolbeck R, Ghosh S, Schwartz TW, and Rosenkilde MM (2007) Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Mol Pharmacol 72:327-340.
13. Johnson M, Li AR, Liu J, Fu Z, Zhu L, Miao S, Wang X, Xu Q, Huang A, and Marcus A et al. (2007) Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 17:3339-3343.
14. Kim SH, Anilkumar GN, Zawacki LG, Zeng Q, Yang DY, Shao Y, Dong G, Xu X, Yu W, and Jiang Y et al. (2011) III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold. Bioorg Med Chem Lett 21:6982-6986.
15. Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, Smit MJ, and Kraneveld AD (2012) Targeting chemokine receptors in chronic inflammatory diseases: An extensive review. Pharmacol Ther 133:1-18.
16. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, and Dioszegi M (2008) Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73:789-800.
17. Kooistra AJ, Roumen L, Leurs R, de Esch IJ, and de Graaf C (2013) From heptahelical bundle to hits from the Haystack: Structure-based virtual screening for GPCR ligands. Methods Enzymol 522:279-336.
18. Lacotte S, Brun S, Muller S, and Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310-317.
19. Liu J, Fu Z, Li AR, Johnson M, Zhu L, Marcus A, Danao J, Sullivan T, Tonn G, and Collins T et al. (2009) Optimization of a series of quinazolinone- derived antagonists of CXCR3. Bioorg Med Chem Lett 19:5114-5118.
20. McGuinness BF, Carroll CD, Zawacki LG, Dong G, Yang C, Hobbs DW, Jacob-Samuel B, Hall JW, 3rd, Jenh CH, and Kozlowski JA et al. (2009) Novel CXCR3 antagonists with a piperazinyl-piperidine core. Bioorg Med Chem Lett 19: 5205-5208.
21. McGuinness BF, Rosenblum SF, Kozlowksi JA, Anilkumar GN, Kim SH, Shih N-Y, Jenh C-H, Zavodny PJ, Hobbs DW, Dong G, et al. (2006) inventors, Schering Corporation, assignee. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity. Patent WO2006088919. 2006 Aug 24.
22. Nedjai B, Li H, Stroke IL, Wise EL, Webb ML, Merritt JR, Henderson I, Klon AE, Cole AG, and Horuk R et al. (2012) Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Br J Pharmacol 166:912-923.
23. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, and Wright TJ et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
24. O'Hayre M, Salanga CL, Handel TM, and Allen SJ (2008) Chemokines and cancer: Migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 409:635-649.
25. Rosenkilde MM, Andersen MB, Nygaard R, Frimurer TM, and Schwartz TW (2007) Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III,-IV, and-VI. Mol Pharmacol 71:930-941.
26. Roumen L, Scholten DJ, de Kruijf P, de Esch IJP, Leurs R, and de Graaf C (2012) C (X)CR in silico: Computer-aided prediction of chemokine receptor-ligand interactions. Drug Discov Today Technol 9:e227-e314.
27. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, and Bradley ME (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159:1429-1439.
28. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, and Leurs R (2012a) Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165:1617-1643.
29. Scholten DJ, Canals M, Wijtmans M, de Munnik SM, Nguyen P, Verzijl D, de Esch IJP, Vischer HF, Smit MJ, and Leurs R (2012b) Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3. Br J Pharmacol 166:898-911.
30. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, and Elling CE (2006) Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev Pharmacol Toxicol 46:481-519.
31. Shao Y, Anilkumar GN, Carroll CD, Dong G, Hall JW, 3rd, Hobbs DW, Jiang Y, Jenh CH, Kim SH, and Kozlowski JA et al. (2011) II. SAR studies of pyridyl-piperazinylpiperidine derivatives as CXCR3 chemokine antagonists. Bioorg Med Chem Lett 21:1527-1531.
32. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, and Han GW et al. (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature 475:65-70.
33. Storelli S, Verdijk P, Verzijl D, Timmerman H, van de Stolpe AC, Tensen CP, Smit MJ, De Esch IJP, and Leurs R (2005) Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists. Bioorg Med Chem Lett 15:2910-2913.
34. Storelli S, Verzijl D, Al-Badie J, Elders N, Bosch L, Timmerman H, Smit MJ, De Esch IJP, and Leurs R (2007) Synthesis and structure-activity relationships of 3Hquinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists. Arch Pharm (Weinheim) 340:281-291.
35. Surgand J-S, Rodrigo J, Kellenberger E, and Rognan D (2006) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62:509-538.
36. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, and Wu B (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387-1390.
37. Tonn GR, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, and Marcus AP et al. (2009) An inhibitory metabolite leads to doseand time-dependent pharmacokinetics of (R)-N-1-[3-(4-ethoxy-phenyl)-4-oxo-3,4- dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-yl-methyl-2-(4- trifluoromethoxyphenyl)-acetamide (AMG 487) in human subjects after multiple dosing. Drug Metab Dispos 37:502-513.
38. Trotta T, Costantini S, and Colonna G (2009) Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: Putative target for new drug design. Mol Immunol 47:332-339.
39. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, and Liang M et al. (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281:27613-27620.
40. van Wanrooij EJ, de Jager SC, van Es T, de Vos P, Birch HL, Owen DA, Watson RJ, Biessen EA, Chapman GA, and van Berkel TJ et al. (2008) CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 28:251-257.
41. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, and Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623.
42. Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, Tensen CP, Fitzsimons CP, Zaman GJ, and Pease JE et al. (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 325: 544-555.
43. Viola A and Luster AD (2008) Chemokines and their receptors: Drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48:171-197.
44. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, and Fulton AM (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66:7701-7707.
45. Watson C, Jenkinson S, Kazmierski W, and Kenakin T (2005) The CCR5 receptorbased mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268-1282.
46. Wijtmans M, de Esch IJP, and Leurs R (2010) Therapeutic targeting of the CXCR3 receptor, in Chemokine Receptors as Drug Targets (Smit MJ, Lira SA, and Leurs R eds) pp 301-322, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany.
47. Wijtmans M, Verzijl D, Bergmans S, Lai M, Bosch L, Smit MJ, de Esch IJP, and Leurs R (2011) CXCR3 antagonists: Quaternary ammonium salts equipped with biphenyl-and polycycloaliphatic-anchors. Bioorg Med Chem 19: 3384-3393.
48. Wijtmans M, Verzijl D, Leurs R, de Esch IJP, and Smit MJ (2008) Towards smallmolecule CXCR3 ligands with clinical potential. ChemMedChem 3:861-872.
49. Wong RSY, Bodart V, Metz M, Labrecque J, Bridger G, and Fricker SP (2008) Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74:1485-1495.
50. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, and Bi FC et al. (2010) Structures of the CXCR4 chemokine GPCR with smallmolecule and cyclic peptide antagonists. Science 330:1066-1071.
51. Xanthou G, Williams TJ, and Pease JE (2003) Molecular characterization of the chemokine receptor CXCR3: Evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33:2927-2936.
52. Zhang J, Chen P, Yuan B, Ji W, Cheng Z, and Qiu X (2013) Real-space identification of intermolecular bonding with atomic force microscopy. Science 342:611-614.